Articles By Wayne Koberstein, Executive Editor

CtW_Craig Thompson_450x300.jpg
Companies To Watch: Neurana
This 10-person startup in San Diego is aiming for muscle-spasm relief without sedation in a purified drug.  Continue Reading..
  • Making Progress On A Micro-Budget

    Started in 2017, Eikonizo Therapeutics has led an uphill battle to getting funding for its pipeline that includes drugs for ALS and Alzheimer’s, among other neurodegenerative diseases.

  • A New Life In Bio

    This unlikely CEO’s experience offers some valuable lessons in founding and scaling up a biotech company, particularly one in a nascent space such as regenerative medicine.

  • Companies To Watch: Adaptive Phage Therapeutics

    Adaptive Phage Therapeutics has created a large catalog of bacteria-killing viruses combined with a diagnostic test to identify and target specific bacterial strains infecting individual patients.

  • A Global Biotech Player From Down Under

    “The other part of being a CEO of a listed company is all about investors, and that was an uphill learning curve for me because I’d never dealt with that aspect,” explains Imugene’s CEO Leslie Chong.

  • Companies To Watch: Imago BioSciences

    In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.

  • Companies To Watch: Scynexis

    Scynexis is creating multiple development programs and a new class of antifungals — all in a single, and singular, drug.

  • Competing Interests Complicate FDA Reform

    With input from two long-time observers of the biopharma industry and its U.S. regulator, this article covers a cross-section of opinions regarding trends and proposals for improving the FDA review process.

  • Crossing Over From Supplier To Sponsor

    What can make a company decide to enter new therapeutic entities into clinical development after decades as a dedicated supplier to bio research labs? Here we explain the reasons and implications of ArunA Bio’s decision.

  • Taking It All The Way To Phase 3 Clinical Trials

    Pluristem offers one example of how a new company in drug development can build the needed infrastructure to maintain its independence as a sponsor.

  • Companies To Watch: Obsidian Therapeutics

    Obsidian Therapeutics targets gene and cell therapies with a technology designed to control the production and activity of therapeutic proteins those therapies induce.

  • Companies To Watch: eXIthera

    This month’s company to watch is eXIthera, which is focused on inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants.

  • Companies To Watch: Leading Biosciences

    Leading Biosciences is applying the science of digestive proteases to treating or preventing multiple diseases and conditions, starting with delayed return of post-surgical bowel function (ileus) and adhesion with its lead product candidate, coded LB1148.

  • Athira’s Whole-Patient Drug Development

    One company is atypical in the industry for its use of patient and caregiver input to guide its drug-development journey. That shows in the program for its lead drug entering later-stage trials in treating Alzheimer’s disease.

  • Meeting Business Challenges By Design, Not Accident

    The story of the business challenges faced by Diasome Pharmaceuticals as it develops its insulin-enhancing delivery technology, which seeks to correct a long-known deficiency in subcutaneous injection of insulin.

wayne koberstein

Wayne Koberstein

Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.